昭衍新药:H股公告:建议进一步更改所得款项净额用途2024-12-21
JOINN LABORATORIES (CHINA) CO., LTD.
6127
(i) H
(ii)
2022 4 28 2023 8 30
6,373.6 5,285.2
2024 11 30 2,713.1
–1–
2024 2024
11 30 11 30
(A)
57.7 57.7 – – –
(i)
16.0 16.0 – – –
(ii)
36.7 36.7 – – –
(iii)
5.0 5.0 – – –
(iv)
– – – – –
(B)
Biomere
751.7 271.2 480.5 – 480.5
(i)
401.7 150.2 251.5 – 251.5 2028
(ii) Biomere
350.0 121.0 229.0 – 229.0 2028
–2–
2024 2024
11 30 11 30
(C)
1,662.8 223.0 1,439.8 (398.5) 1,041.3
(i)
GLP GLP
500.0 176.5 323.5 – 323.5 2027
(ii)
898.5 11.7 886.8 (398.5) 488.3 2028
(iii)
137.4 34.8 102.6 – 102.6 2028
(iv)
126.9 – 126.9 – 126.9 2028
(D)
264.3 33.1 231.2 (231.2) –
(i) 220
31.7 8.4 23.3 (23.3) –
–3–
2024 2024
11 30 11 30
(ii)
21.2 – 21.2 (21.2) –
(iii)
211.4 24.7 186.7 (186.7) –
(E) (i)
(ii)
(iii)
2,020.2 1,895.7 124.5 629.7 754.2 2028
(F)
528.5 232.4 296.1 – 296.1
5,285.2 2,713.1 2,572.1 2,572.1
–4–
(i)
Biomere 2028 12 (ii)
2027 12 2028 12
398.5 (iii)
231.2 (iv)
2028 12
2024 12 20
–5–